A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 836 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma May 20, 2026 Research with integrity – the importance of communication November 14, 2022 Returning to Dental Care August 24, 2020 European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening... January 22, 2026 Load more HOT NEWS ESMO Launches Its Roadmap 2030 to Support Oncology Professionals and Foster... Though the Pandemic Has Slowed, Many Are Still Struggling to Put... Patient Guide in Bladder Cancer Now Available Also in Italian Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer
